The rs1800469 T/T and rs1800470 C/C genotypes of the TGFB1 gene confer protection against diabetic retinopathy in a Southern Brazilian population

Abstract

The transforming growth factor beta 1 (TGFB1) is a pro-inflammatory cytokine that plays a key role in the mechanisms of angiogenesis and breakdown of the blood-retina barrier, which are implicated in the pathogenesis of diabetic retinopathy (DR). Polymorphisms in the TGFB1 gene have been associated with DR; however, results are still contradictory. Therefore, the aim of this study was to investigate the potential association between two TGFB1 polymorphisms and DR. This study included 992 patients with diabetes mellitus (DM): 546 patients with DR (cases) and 446 patients without DR and with ≥10 years of DM (controls). The TGFB1 rs1800469 and rs1800470 polymorphisms were genotyped by real-time PCR. Frequency of rs1800469 T/T genotype was higher in controls compared to DR cases (18.3% vs. 12.7%, P= 0.022). This genotype remained associated with protection for DR, adjusting for covariables (OR= 0.604; 95% CI 0.395 - 0.923; P= 0.020, recessive model). The rs1800470 C/C genotype was observed in 25.4% of the controls and 18.0% of the cases (P= 0.015); thus, being associated with protection against DR under the recessive model (OR= 0.589; 95% CI 0.405 - 0.857; P= 0.006), adjusting for covariables. In conclusion, the TGFB1 rs1800469 and rs1800470 polymorphisms are associated with protection against DR in DM patients from Southern Brazil.

Keywords:
Diabetic retinopathy; polymorphisms; rs1800470; rs1800469; TGFB1

Introduction

Diabetic retinopathy (DR) is a common chronic microvascular complication of diabetes mellitus (DM) and represents the primary cause of visual impairment and loss in working-aged adults (Cheung et al., 2010; Solomon et al., 2017; Kusuhara et al., 2018). DR affects approximately 35% of DM patients, being more frequent in type 1 DM (T1DM) than in type 2 DM (T2DM) patients (Yau et al., 2012). Its prevalence increases with DM duration, with ≅ 86% of T1DM and 52% of T2DM patients showing some degree of DR after 20 years of DM duration (Yau et al., 2012). Although the risk of DR increases with poor glycemic control, long-term DM, arterial hypertension (AH), dyslipidemia, and body mass index (BMI), available evidence has suggested its development is also influenced by genetic factors (Cho and Sobrin, 2014; Priščáková et al., 2016; Han et al., 2019). In this context, chronic hyperglycemia and other risk factors initiate a cascade of biochemical and physiological alterations that can culminate in microvascular damage and subsequent retinal dysfunction. These changes are linked to retinal ischemia, abnormal angiogenesis, and increased vascular permeability due to breakdown of the blood-retina barrier (Cheung et al., 2010; Kusuhara et al., 2018).

The transforming growth factor beta 1 (TGFB1) is a pro-fibrotic and pro-inflammatory cytokine that modulates cell proliferation, differentiation, apoptosis, adhesion, and migration of several cell types, and induces the production of extracellular matrix (ECM) proteins (Loeffler and Wolf, 2014). Given its critical roles in angiogenesis, endothelial proliferation, ECM deposition, and breakdown of the blood-retina barrier, TGFB1 represents a candidate gene for susceptibility to DR as well as other chronic diabetic complications, including diabetic kidney disease (DKD) (Khan and Chakrabarti, 2003; Jia et al., 2011; Liu et al., 2014). Accordingly, several studies have associated single nucleotide polymorphisms (SNPs) in the TGFB1 gene with susceptibility for DR and/or DKD (Beránek et al., 2002; Buraczynska et al., 2007; Jia et al., 2011; Bazzaz et al., 2014; Liu et al., 2014; Hampton et al., 2015; Zhou et al., 2018; Zhou et al., 2019).

The T allele of rs1800470 (c.+29 T>C, Leu10Pro) SNP in the TGFB1 gene was initially associated with risk for proliferative DR (PDR) in patients with T2DM from the Czech population (Beránek et al., 2002). Conversely, another study reported that the C allele conferred risk for DR in patients with T2DM from Poland (Buraczynska et al., 2007). In 2014, Liu et al. (Liu et al., 2014) published a meta-analysis including 3 studies that investigated the association between the rs1800469 (c.-1347 C>T) SNP and DR; however, no significant association was found. Beránek et al. (Beránek et al., 2002) reported that a haplotype constituted by both rs1800470 T and rs1800469 C alleles conferred increased risk for PDR. Due to the contradictory results, additional studies are needed to clarify whether these SNPs are associated with DR.

Therefore, as part of the ongoing effort to examine the hypothesis that TGFB1 SNPs are associated with DR, this study aims to investigate the association of rs1800469 (c.-1347 C>T) and rs1800470 (c.+29 T>C) SNPs in the TGFB1 gene with DR in both T1DM and T2DM from a Southern Brazilian population.

Material and Methods

DM patients, phenotype measurements, and laboratory analyses

This case-control study was designed following STROBE and STREGA guidelines for reporting genetic association studies (von Elm et al., 2008; Little et al., 2009). The study population consisted of 992 DM patients, including 546 cases with DR and 446 controls without this complication and with a known DM duration of at least 10 years. Of note, of the total sample with DM, 727 (73.3%) patients had T2DM and 156 patients had T1DM (26.7%). All included patients were recruited from the outpatient clinic at the Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil) between January 2005 and December 2013 (Crispim et al., 2010; Massignam et al., 2020). The research protocol was approved by the Ethics Committee in Research from Hospital de Clínicas de Porto Alegre, and all subjects provided assent and written informed consent prior to the inclusion in the study.

Patients were diagnosed as having DM according to American Diabetes Association guidelines (American Diabetes Association, 2020). Assessment of DR was performed by an experienced ophthalmologist using fundoscopy through dilated pupils. DR was classified as ‘absent DR’ (no fundus abnormalities), non-proliferative DR (NPDR, presence of microaneurysms, intraretinal hemorrhages, and hard exudates) or proliferative DR (PDR, newly formed blood vessels and/or growth of fibrous tissue into the vitreous cavity). DR classification was done considering the most severely affected eye, according to the Global Diabetic Retinopathy Group scale (Wilkinson et al.,, 2003).

A standard questionnaire was used to collect information about age, age at DM diagnosis, type and DM duration, and drug treatment. Moreover, all patients underwent complete physical and laboratory evaluations, as previously reported by our group (Crispim et al., 2010; Bouças et al., 2013; Massignam et al., 2020). Ethnicity was defined based on self-classification, and patients were categorized in white and non-white subjects (Crispim et al., 2010). Serum and plasma samples were taken after 12 h of fasting for laboratory analyses. Glucose levels were determined using the glucose oxidase method. Glycated hemoglobin (HbA1c) levels were measured by different methods and the results were traceable to the Diabetes Control and Complications Trial (DCCT) method by off-line calibration or using a conversion formulae (Camargo et al., 1998). Creatinine was measured by the Jaffé reaction; total plasma cholesterol, HDL cholesterol and triglycerides by enzymatic methods, and urinary albumin excretion (UAE) by immunoturbidimetry (Sera-Pak immuno microalbuminuria, Bayer, Tarrytown, NY, USA) (Zelmanovitz et al., 1997). The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (Levey et al., 2009). Body mass index (BMI) was calculated as weight (kg)/height (meters)².

Genotyping

Total DNA was extracted from peripheral blood samples using a standardized technique. TGFB1 rs1800469 (c.-1347 C>T; C-509T) and rs1800470 (c.+29 T>C; T869C; Leu10Pro) SNPs were genotyped using TaqMan SNP Genotyping Assays 20X (Thermo Fisher Scientific, Foster City, CA, USA; Assay ID: C_8708473_10 and C_22272997_10, respectively). Real-Time PCR reactions were performed in 384-well plates, in a total 5 µL volume, using 2 ng of DNA, TaqMan Genotyping Master Mix 1X (Thermo Fisher Scientific) and TaqMan Genotyping Assay 1X. PCR reactions were performed in a real-time PCR thermal cycler (ViiA7 Real-Time PCR System; Thermo Fisher Scientific).

Haplotype distributions and linkage disequilibrium (LD) analysis

The haplotypes constructed by the combination of the rs1800469 and rs1800470 TGFB1 SNPs and their frequencies were inferred using the Phase 2.1 program (Seattle, WA, USA), which implements a Bayesian statistical method (Stephens et al., 2001). We also used this program to compare the distributions of different TGFB1 haplotypes between DR patients and control subjects through permutation analyses of 10, 000 random replicates (Stephens et al., 2001). Linkage disequilibrium (LD) between the two SNPs was calculated using Lewontin´s D´|D´| and r ² measurements (Hedrick 1987).

Statistical analyses

Allele frequencies were determined by gene counting, and departures from the Hardy-Weinberg Equilibrium (HWE) were assessed using the χ² test. Allele and genotype frequencies were compared between groups of subjects using χ² tests. Moreover, genotypes were compared between case and control groups considering additive, recessive, and dominant inheritance models (Zintzaras and Lau, 2008). Normal distributions of quantitative clinical and laboratory variables were checked using Kolmogorov-Smirnov and Shapiro-Wilk tests. Variables with normal distribution are shown as mean ± SD. Variables with skewed distribution were log-transformed before analysis and are shown as median (25th - 75th percentile values). Categorical data are shown as percentages.

Clinical and laboratory characteristics were compared between case and control patients and between groups of patients categorized according to the different genotypes of the two TGFB1 SNPs using appropriate statistical tests, such as Student’s t-test or χ² tests. Bonferroni’s correction was applied to account for multiple comparisons for unpaired Student’s t tests or χ² tests.

The magnitude of association between TGFB1 SNPs and DR was estimated using odds ratios (OR) with 95% confidence intervals (CI). Multivariate logistic regression analyses were done to evaluate the independent association of each individual TGFB1 SNP or haplotypes with DR, adjusting for possible confounding factors. Statistical analyses were performed using the SPSS 18.0 software (SPSS, Chicago, IL), and P values < 0.05 were considered significant. Sample size was calculated using the OpenEpi site (http://www.openepi.com) and the minor allele frequencies and ORs observed in previous studies regarding associations of the rs1800469 and rs1800470 SNPs with DR (Beránek et al., 2002; Paine et al., 2012; Rodrigues et al., 2015).

Results

Sample description

The clinical and laboratorial characteristics of DR cases and controls are shown in Table 1. Males comprised 52.6% of the case group and 44.2% of the control group (P = 0.010), and the mean age was 62.5 ± 15.1 years in cases and 59.5 ± 20.1 in controls (P = 0.010). The mean DM duration was higher in cases compared to controls (23.3 ± 9.2 vs. 21.4 ± 9.0; P = 0.002). As expected, mean levels of LDL, triglycerides and UAE, as well as prevalence of AH were significantly higher in cases compared to control subjects (all P < 0.003). Ethnic distribution, BMI, HbA1c, total cholesterol, and HDL cholesterol levels did not differ significantly between groups (Table 1).

Table 1 -
Clinical and laboratory characteristics of DM patients without and with DR.

Characteristics	Controls (n = 446)	Cases with DR (n = 546)	P *
Age (years)	59.5 ± 20.1	62.5 ± 15.1	0.010
Gender (% males)	197 (44.2)	287 (52.6)	0.010
Ethnicity (% non-white)	64 (14.3)	91 (16.7)	0.358
T2DM patients (%)	305 (68.5)	422 (77.3)	0.002
DM duration (years)	21.4 ± 9.0	23.3 ± 9.2	0.002
BMI (kg/m²)	27.8 ± 5.2	27.9 ± 5.1	0.747
HbA1c (%)	7.8 ± 1.9	8.2 ± 2.1	0.015
Cholesterol total (mg/dL)	189.1 ± 49.0	198.0 ± 51.6	0.007
HDL cholesterol (mg/dL)	49.7 ± 14.0	48.5 ± 14.7	0.182
LDL cholesterol (mg/dL)	108.9 ± 41.4	117.6 ± 45.0	0.002
Triglycerides (mg/dL)	127.0 (75.0 - 189.0)	133.5 (32.7 - 86.0)	0.001
Arterial hypertension (%)	322 (72.2)	477 (87.4)	0.0001
eGFR (ml/min per 1.73 m2)	83.5 (61.0 - 100.0)	62.0 (32.7 - 86.0)	0.102
UAE (mg/g)	8.0 (4.0 - 30.5)	54.9 (9.3 - 381.5)	0.0001

• Variables are shown as mean ± SD, median (25th-75th percentiles) or absolute number (%). *P-values were computed using Student’s t or χ² tests, as appropriate. OnlyPvalues lower than the Bonferroni’s threshold (P= 0.0035) were considered statistically significant. BMI: body mass index; DM: diabetes mellitus; DR: diabetic retinopathy; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin; T2DM: type 2 diabetes mellitus; UAE: urinary albumin excretion.

Distributions of the TGFB1 rs1800469 and rs1800470 SNPs in case and control groups

Genotype frequencies of the rs1800469 (c.-1347 C>T) and rs1800470 (c.+29 T>C) SNPs in the TGFB1 gene are in HWE in the case group (all P > 0.05). Frequencies of rs1800469 T/T and rs1800470 C/C genotypes did not differ significantly between white and non-white subjects (rs1800469 T/T: 15.0 vs. 17.2%, respectively; P = 0.354; rs1800470 C/C: 20.8 vs. 25.8%, P = 0.188). Moreover, frequencies of these genotypes did not differ between T1DM and T2DM patients (rs1800469 T/T: 15.3 vs. 15.2%, respectively; P = 0.893; rs1800470 C/C: 19.9 vs. 22.1%; P = 0.595). Hence, both white and non-white subjects, as well as patients with T1DM and T2DM, were analyzed together.

Table 2 shows genotype and allele frequencies of the rs1800469 and rs1800470 SNPs in patients with DM (T1DM + T2DM) categorized into DR cases and non-DR controls. Frequency of the T/T genotype of the rs1800469 SNP was 18.3% in controls and 12.7% in cases with DR (P = 0.022). After adjustment for HbA1c, AH, UAE, and triglycerides, the T/T genotype remained associated with protection against DR in the recessive model (OR = 0.604; 95% CI 0.395 - 0.923; P = 0.020). Regarding the rs1800470 SNP, the frequency of the C/C genotype was 25.4% in controls and 18.0% in cases with DR (P = 0.015). In the recessive model, the rs1800470 T/T genotype was also found to be associated with protection against DR, independent of the variables described above (OR = 0.589; 95% CI 0.405 - 0.857; P = 0.006).

Table 2 -
Genotype and allele frequencies of TGFB1 rs1800469 and rs1800470 SNPs in DM patients without and with DR.

rs1800469	Controls (n = 437)	Cases with DR (n = 529)	Unadjusted P*	Adjusted OR (95% IC) / P†
Genotype
C/C	182 (41.6)	214 (40.5)	0.022	1
C/T	175 (40.0)	248 (46.8)		1.267 (0.910 - 1.765)/ 0.161
T/T	80 (18.4)	67 (12.7)		0.680 (0.431 - 1.073)/ 0.097
Allele
C	0.62	0.64	0.337
T	0.38	0.36
Recessive model
C/C + C/T	357 (81.7)	462 (87.3)	0.019	1
T/T	80 (18.3)	67 (12.7)		0.604 (0.395 - 0.923)/ 0.020
Additive model
C/C	182 (69.5)	214 (76.2)	0.098	1
T/T	80 (30.5)	67 (23.8)		0.656 (0.410 - 1.051)/ 0.079
Dominant model
C/C	182 (41.6)	214 (40.5)	0.757	1
C/T + T/T	255 (58.4)	315 (59.5)		1.075 (0.790 - 1.462)/ 0.645
rs1800470	Controls (n = 426)	Cases with DR (n = 512)	Unadjusted P*	Adjusted OR (95% IC) / P†
Genotype
T/T	136 (31.9)	165 (32.2)	0.015	1
T/C	182 (42.7)	255 (49.8)		1.255 (0.882 - 1.786)/ 0.207
C/C	108 (25.4)	92 (18.0)		0.673 (0.439 - 1.031)/ 0.069
Allele
T	0.53	0.57	0.105
C	0.47	0.43
Recessive model
T/T + T/C	318 (74.6)	420 (82.0)	0.008	1
C/C	108 (25.4)	92 (18.0)		0.589 (0.405 - 0.857)/ 0.006
Additive model
T/T	136 (55.7)	165 (64.2)	0.065	1
C/C	108 (44.3)	92 (35.8)		0.674 (0.437 - 1.039)/ 0.074
Dominant model
T/T	136 (31.9)	165 (32.2)	0.977	1
T/C + C/C	290 (68.1)	347 (67.8)		1.026 (0.740 - 1.423)/ 0.876

• Data are shown as number (%) or proportion. *P-values were calculated using χ² tests. OnlyPvalues lower than the Bonferroni’s threshold (P= 0.010) were considered statistically significant. † P-value and OR (95% CI) obtained using logistic regression analyses adjusting for HbA1c, AH, UAE and triglycerides levels.

Haplotype distributions and LD

Frequencies of haplotypes produced by the combination of TFGB1 rs1800469 and rs1800470 SNPs in cases and controls are listed in Table 3. Four haplotypes were inferred in both samples and their distributions were not significantly different between case and control groups (P = 0.564). It is noteworthy that the two SNPs of interest are in partial LD in our population (|D′| = 0.679 and r² = 0.335).

Table 3 -
Haplotypes of the TGFB1 SNPs in DM patients without and with DR.

Haplotypes	Controls	Cases with DR	P *
TT	0.086	0.088	0.564
TC	0.522	0.548
CT	0.379	0.355
CC	0.013	0.009

• Data are presented as proportion. The first letter of the haplotypes refers to the rs1800470 SNP and the second to the rs1800469 SNP. *Permutation P-value was computed for comparisons of haplotype frequencies between groups.

Next, in order to increase statistical power, we further analyzed haplotype frequencies according to the number of minor alleles in haplotypes: a) subjects carrying 0, 1 or 2 minor alleles of rs1800469 and rs1800470 SNPs, and b) subjects carrying 3 or 4 minor alleles (Figure 1). Frequency of 3 or 4 minor alleles of the two analyzed SNPs was lower in DR cases compared to controls (16.8% vs. 24.0; P = 0.008; Figure 1). Moreover, after adjustment for AH, HbA1c, UAE, and triglycerides levels, the presence of ≥3 minor alleles remained independently associated with protection against DR (OR = 0.549; 95% CI 0.371 - 0.812; P = 0.003). The observed OR is similar to those obtained for each SNP analyzed individually, suggesting that their effects on DR susceptibility may not be additive.

Figure 1 -
DR cases and DM controls were categorized by the number of risk alleles of the analyzed polymorphisms in the estimated haplotypes. Data are presented as percentage. P= 0.008 was obtained using the χ²-test and considering the absolute number of patients in each category.

Discussion

TGFB1 has been recognized as a key factor in the pathogenesis of chronic microvascular complications of DM (Jia et al., 2011; Liu et al., 2014). Accordingly, SNPs in the TGFB1 gene have been shown to be involved in the susceptibility for DKD due to the role of this gene on tissue fibrosis processes (Buraczynska et al., 2007; Jia et al., 2011; Zhou et al., 2018; Varghese and Kumar, 2019; Zhou et al., 2019). Moreover, TGFB1 SNPs seem to be associated with susceptibility for DR (Paine et al., 2012; Liu et al., 2014; Hampton et al., 2015); however, available data is less convincing. Thus, in this study, we investigated the association of TGFB1 rs1800469 and rs1800470 SNPs with DR in T1DM and T2DM patients from a Southern Brazilian population. Our findings suggest that both SNPs are associated with protection against DR.

The rs1800469 SNP (c.-1347 C>T; also known as C-509T) is situated in the first negative regulatory region of the upstream promoter of the TGFB1 gene, and the T allele seems to increase both TGFB1 gene expression and circulating plasma levels in humans (Grainger et al., 1999; Shah et al., 2006; Martelossi Cebinelli et al., 2016). Interestingly, TGFB1 concentration seems to be higher in T/T homozygous than heterozygous, suggesting a dose-response effect (Grainger et al., 1999). Elevated TGFB1 plasma levels have been associated with the progression of renal disease due to increased ECM production, leading to glomerulosclerosis and tubulointerstitial fibrosis (Loeffler and Wolf, 2014). In the context of DR pathogenesis, augmented TGFB1 circulating levels might enhance angiogenesis and endothelial proliferation, as well as ECM production and blood-retina barrier breakdown, thereby contributing to the development and progression of DR (Khan and Chakrabarti, 2003; Jia et al., 2011; Liu et al., 2014).

Besides functional studies reporting the impact of the rs1800469 T allele on TGFB1 levels, the association of this SNP with diabetic chronic complications remains inconclusive. Our present case-control study demonstrated a significant association of the T/T genotype with protection against DR. Consistent with our findings, the C allele of this SNP was found to be more prevalent in PDR patients (P = 0.050), and this allele was associated with risk of PDR in the haplotype constituted together with the rs1800470 SNP (Beránek et al., 2002). In contrast, the meta-analysis conducted by Liu et al. (Liu et al., 2014) did not reveal any significant association between this SNP and DR. These discrepant findings may be explained by differences in ethnicities since the studies included in the meta-analysis involved T2DM patients from Czech, Poland, and India populations (Liu et al., 2014). Moreover, the meta-analysis only included 3 studies comprising 521 T2DM patients with DR and 580 controls, raising the possibility of insufficient statistical power. Furthermore, Raina et al. (2015) demonstrated that the T/T genotype of rs1800469 SNP was associated with a 5.5-fold increased risk of end-stage renal disease (ESRD) in T2DM patients from North India. However, other studies have not been able to find any association between this SNP and DKD (Ng et al., 2003; McKnight et al., 2007; Prasad et al., 2007). Although functional studies suggest that the rs1800469 T allele leads to worse outcomes related to the pathogenesis of microvascular diabetic complications, the results of case-control studies that investigated this SNP in DM patients are still contradictory. Therefore, more studies with larger sample sizes are necessary to better understand the involvement of the rs1800469 SNP in DM and DR susceptibility.

The rs1800470 SNP (c.+29 T>C; also known as T869C) causes the replacement of a Leucine (Leu) to a Proline (Pro) in codon 10 (Leu10Pro) of exon 1, which encodes the N-terminal signal peptide of TGFB1 (Martelossi Cebinelli et al., 2016). Although it has been speculated that modifications in amino acid composition of the signal peptide can affect its polarity and lead to different rates of protein export (Wood et al., 2000), both T and C alleles encode nonpolar amino acids (Martelossi Cebinelli et al., 2016), suggesting they have similar effects on protein function. An in vitro study showed that the C (Pro) allele caused an increase in TGFB1 secretion compared to the T (Leu) allele (Dunning et al., 2003). Moreover, studies have shown that serum TGFB1 concentration is higher in subjects with the C/C genotype compared to T allele carriers (Yokota et al., 2000; Taubenschuss et al., 2013; Martelossi Cebinelli et al., 2016). However, Ramirez et al. (2020) demonstrated that individuals carrying the T/T genotype have higher levels of TGFB1 when compared to C/C carriers. Hence, although the functional effect of this SNP on TGFB1 expression is not yet clear, higher levels of TGFB1 can increase angiogenesis, ECM production, and blood-retina breakdown, thus predisposing to DR.

Our present study reported an association between the C/C genotype of the rs1800470 SNP and protection against DR. Supporting a protective role of the C allele, Javor et al. (2010) demonstrated an association between the T/T genotype and an increased risk for DR in T1DM patients from a Slovak population. Similarly, another study showed that the T allele is associated with risk for PDR (OR = 2.89; 95% CI 1.6 - 5.1) in T2DM patients from the Czech Republic (Beránek et al., 2002). In contrast, Buraczynska et al., (2007) reported that the C allele of this SNP was associated with increased risk of DR (OR = 2.22; 95% CI 1.64 - 2.99) in T2DM patients from Poland. Bazzaz et al. (2014) also reported that the frequency of the C allele was higher in T1DM patients with DR compared to controls, although the difference did not reach statistical significance. Moreover, a small study of Brazilian T2DM patients (66 cases with DR and 36 controls) did not find any significant association between the rs1800470 SNP and DR (Rodrigues et al., 2015).

In 2011, Jia et al. (2011) published a meta-analysis of nine studies (1776 cases and 1740 controls) investigating the association between the rs1800470 SNP and DKD in T1DM or T2DM patients, which suggested that the presence of the C allele was associated with an increased risk for DKD (OR = 1.25, 95% CI 1.05 - 1.48). A recent meta-analysis of eight Chinese studies (1018 cases with DKD and 941 controls) reported that the T/T genotype conferred protection against DKD (OR = 0.55, 95% CI 0.31 - 0.96) in T2DM patients (Zhou et al., 2018). Despite the new data generated by our article, the results remain contradictory, and additional studies are necessary to clarify the association between this SNP and DR.

This study has a few limitations. First, even though ethnic distributions were similar between case and control groups, there is a possibility of population stratification bias when analyzing the samples. Second, although the frequencies of the rs1800469 and rs1800470 SNPs were similar between T1DM and T2DM patients, the sample size was not sufficient to conduct further stratification analysis by DM type. Therefore, the possibility that the strength of association of these SNPs with DR might be different between DM types cannot be ruled out. Third, due to small sample sizes and the number of independent variables included in the models, corrections for multiple comparisons were not applied in logistic regression analyses. Thus, further studies are needed to confirm the results of this study.

In conclusion, this study suggests that the TGFB1 rs1800469 and rs1800470 SNPs may confer protection against DR in T1DM and T2DM patients from Southern Brazil. Nevertheless, further research is necessary to confirm the role of these SNPs in the development of DR.

Acknowledgements

This study was partially supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundo de Incentivo à Pesquisa e Eventos (FIPE) at Hospital de Clínicas de Porto Alegre (grant number: 2019-0390), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS) (Edital FAPERGS/CNPq PRONEX 12/2014: 16-2551-0000476-5), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Graduate Program in Medical Sciences: Endocrinology - Universidade Federal do Rio Grande do Sul. D.C. and L.H.C are recipient of a scholarship from CNPq, while A.R.C. and C.D. are recipients from scholarships from CAPES.

References

• American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care 43:S14-S31.
• Bazzaz JT, Amoli MM, Taheri Z, Larijani B, Pravica V and Hutchinson IV (2014) TGF-beta1 and IGF-I gene variations in type 1 diabetes microangiopathic complications. J Diabetes Metab Disord 13:45.
• Beránek M, Kanková K, Benes P, Izakovicová-Hollá L, Znojil V, Hájek D, Vlková E and Vácha J (2002) Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. Am J Med Genet 109:278-283.
• Bouças AP, Brondani LA, Souza BM, Lemos NE, de Oliveira FS, Canani LH and Crispim D (2013) The A allele of the rs1990760 polymorphism in the IFIH1 gene is associated with protection for arterial hypertension in type 1 diabetic patients and with expression of this gene in human mononuclear cells. PLoS One 8:e83451.
• Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E and Ksiazek A (2007) TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol 106:69-75.
• Camargo JL, Zelmanovitz T, Paggi A, Friedman R and Gross JL (1998) Accuracy of conversion formulae for estimation of glycohaemoglobin. Scand J Clin Lab Invest 58:521-528.
• Cheung N, Mitchell P and Wong TY (2010) Diabetic retinopathy. Lancet 376:124-136.
• Cho H and Sobrin L (2014) Genetics of diabetic retinopathy. Curr Diab Rep 14:515.
• Crispim D, Fagundes NJ, dos Santos KG, Rheinheimer J, Boucas AP, de Souza BM, Macedo GS, Leiria LB, Gross JL and Canani LH (2010) Polymorphisms of the UCP2 gene are associated with proliferative diabetic retinopathy in patients with diabetes mellitus. Clin Endocrinol (Oxf) 72:612-619.
• Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V et al (2003) A transforming growth factor-beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610-2615.
• Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND and Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93-97.
• Hampton BM, Schwartz SG, Brantley MA Jr. and Flynn HW Jr. (2015) Update on genetics and diabetic retinopathy. Clin Ophthalmol 9:2175-2193.
• Han J, Lando L, Skowronska-Krawczyk D and Chao DL (2019) Genetics of diabetic retinopathy. Curr Diab Rep 19:67.
• Hedrick PW (1987) Gametic disequilibrium measures: Proceed with caution. Genetics 117:331-341.
• Javor J, Ferencik S, Bucova M, Stuchlikova M, Martinka E, Barak L, Strbova L, Grosse-Wilde H and Buc M (2010) Polymorphisms in the genes encoding TGF-beta1, TNF-alpha, and IL-6 show association with type 1 diabetes mellitus in the Slovak population. Arch Immunol Ther Exp (Warsz) 58:385-393.
• Jia H, Yu L, Gao B and Ji Q (2011) Association between the T869C polymorphism of transforming growth factor-beta 1 and diabetic nephropathy: A meta-analysis. Endocrine 40:372-378.
• Khan ZA and Chakrabarti S (2003) Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res 4:287-301.
• Kusuhara S, Fukushima Y, Ogura S, Inoue N and Uemura A (2018) Pathophysiology of diabetic retinopathy: The old and the new. Diabetes Metab J 42:364-376.
• Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604-612.
• Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J et al (2009) STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest 39:247-266.
• Liu L, Jiao J, Wang Y, Wu J, Huang D, Teng W and Chen L (2014) TGF-beta1 gene polymorphism in association with diabetic retinopathy susceptibility: A systematic review and meta-analysis. PLoS One 9:e94160.
• Loeffler I and Wolf G (2014) Transforming growth factor-β and the progression of renal disease. Nephrol Dial Transplant 29:i37-i45.
• Martelossi Cebinelli GC, Paiva Trugilo K, Badaro Garcia S and Brajao de Oliveira K (2016) TGF-beta1 functional polymorphisms: A review. Eur Cytokine Netw 27:81-89.
• Massignam ET, Dieter C, Pellenz FM, Assmann TS and Crispim D (2020) Involvement of miR-126 rs4636297 and miR-146a rs2910164 polymorphisms in the susceptibility for diabetic retinopathy: A case-control study in a type 1 diabetes population. Acta Ophthalmol 99:e461-e469.
• McKnight AJ, Savage DA, Patterson CC, Sadlier D and Maxwell AP (2007) Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC Med Genet 8:5.
• Ng DP, Warram JH and Krolewski AS (2003) TGF-beta 1 as a genetic susceptibility locus for advanced diabetic nephropathy in type 1 diabetes mellitus: An investigation of multiple known DNA sequence variants. Am J Kidney Dis 41:22-28.
• Paine SK, Basu A, Mondal LK, Sen A, Choudhuri S, Chowdhury IH, Saha A, Bhadhuri G, Mukherjee A and Bhattacharya B (2012) Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Mol Vis 18:2749-2757.
• Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R and Thelma BK (2007) Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 8:20.
• Priščáková P, Minárik G and Repiská V (2016) Candidate gene studies of diabetic retinopathy in human. Mol Biol Rep 43:1327-1345.
• Raina P, Sikka R, Kaur R, Sokhi J, Matharoo K, Singh V and Bhanwer AJ (2015) Association of transforming growth factor beta-1 (TGF-β1) genetic variation with type 2 diabetes and end stage renal disease in two large population samples from North India. OMICS 19:306-317.
• Ramirez A, Hernandez M, Suarez-Sanchez R, Ortega C, Peralta J, Gomez J, Valladares A, Cruz M, Vazquez-Moreno MA and Suarez-Sanchez F (2020) Type 2 diabetes-associated polymorphisms correlate with SIRT1 and TGF-beta1 gene expression. Ann Hum Genet 84:185-194.
• Rodrigues KF, Pietrani NT, Sandrim VC, Vieira CM, Fernandes AP, Bosco AA and Gomes KB (2015) Association of a large panel of cytokine gene polymorphisms with complications and comorbidities in type 2 diabetes patients. J Diabetes Res 2015:605965.
• Shah R, Rahaman B, Hurley CK and Posch PE (2006) Allelic diversity in the TGFB1 regulatory region: Characterization of novel functional single nucleotide polymorphisms. Hum Genet 119:61-74.
• Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, Wykoff CC and Gardner TW (2017) Diabetic retinopathy: A position statement by the American Diabetes Association. Diabetes Care 40:412-418.
• Stephens M, Smith NJ and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
• Taubenschuss E, Marton E, Mogg M, Frech B, Ehart L, Muin D and Schreiber M (2013) The L10P polymorphism and serum levels of transforming growth factor beta1 in human breast cancer. Int J Mol Sci 14:15376-15385.
• Varghese S and Kumar SG (2019) Association between genetic variants of NOS3, TGF-β and susceptibility of diabetic nephropathy: A meta-analysis. Meta Gene 21:100573.
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP and STROBE I (2008) [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies]. Rev Esp Salud Publica 82:251-259.
• Wilkinson CP, FerrisFL3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677-1682.
• Wood NA, Thomson SC, Smith RM and Bidwell JL (2000) Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP. J Immunol Methods 234:117-122.
• Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556-564.
• Yokota M, Ichihara S, Lin TL, Nakashima N and Yamada Y (2000) Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 101:2783-2787.
• Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M and Azevedo MJ (1997) The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 20:516-519.
• Zhou D, Mou X, Liu K, Liu W, Xu Y and Zhou D (2019) Association between transforming growth factor-β1 T869C gene polymorphism and diabetic nephropathy: A meta-analysis in the Chinese population. Clin Lab 65.
• Zhou T, Li HY, Zhong H and Zhong Z (2018) Relationship between transforming growth factor-β1 and type 2 diabetic nephropathy risk in Chinese population. BMC Med Genet 19:201.
• Zintzaras E and Lau J (2008) Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634-645.

Edited by

Associate Editor:

Angela Maria Vianna-Morgante

Publication Dates

• Publication in this collection
  07 July 2023
• Date of issue
  2023

History

• Received
  11 Aug 2022
• Accepted
  30 Apr 2023